Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2009 - 2026)

Alnylam Pharmaceuticals has reported Cash from Investing Activities for 18 years, with the latest figure at -$25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 122.45% year-over-year to -$25.5 million; the trailing twelve-month figure through Mar 2026 stood at $297.0 million (up 360.14% YoY), and the FY2025 full-year result was $436.3 million, up 473.44% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$25.5 million, up from -$37.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $501.1 million in Q3 2025, with the low at -$240.7 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged $7.5 million across 5 years, with a median of -$30.2 million in 2024.
• The largest YoY upside for Cash from Investing Activities was 1756.55% in 2025 against a maximum downside of 516.56% in 2025.
• Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$139.9 million in 2022, then slumped by 72.01% to -$240.7 million in 2023, then jumped by 78.01% to -$52.9 million in 2024, then advanced by 29.76% to -$37.2 million in 2025, then surged by 31.28% to -$25.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$25.5 million (Q1 2026), -$37.2 million (Q4 2025), and $501.1 million (Q3 2025), per Business Quant data.